

The Eicosanoids, a Family of Bioactive Compounds

Jesús Balsinde

*Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas (CSIC),
47003 Valladolid, Spain*

January 1, 2011

The eicosanoids are a family of bioactive compounds that derive from the enzymatic oxygenation of arachidonic acid (AA). Prostaglandins, leukotrienes, thromboxane, lipoxins, are all members of the eicosanoid family. The eicosanoids are biomedically important because they mediate all four signs of inflammation, namely heat, redness, swelling and pain. Controlling the formation of eicosanoids has been found to be of great benefit for the treatment of acute and chronic inflammatory diseases.

(Results & Publications sections, up to 2011 – The Eicosanoid Research Division – www.balsinde.org)



AA seldom occurs in free form in resting cells. It is mostly found esterified at the sn-2 position of cellular phospholipids. This is so because in resting cells the mechanisms for AA incorporation into phospholipids dominate over the hydrolytic mechanism for AA release. Thus, due to the very low level of free AA, unstimulated cells produce only modest amounts of eicosanoids.

AA incorporation into phospholipids is critically dependent on the availability of lysophospholipid acceptors, particularly lysophosphatidylcholine (lysoPC). Once the AA is initially incorporated into lysoPC by the action of CoA-dependent acyltransferases, it is then transferred to certain lysophospholipids, particularly the ethanolamine lysophospholipids (lysoPE). Thus, for the AA to be efficiently incorporated into phospholipids, two kinds of lysophospholipid acceptors should be readily available. These acceptors are provided by intracellular phospholipase A₂ (PLA₂) enzymes. A particular PLA₂ form, called Group VIA calcium-independent PLA₂ (iPLA₂-VIA), appears to play a key role in regulating the steady-state level of lysoPC in some cells. These include phagocytes, which are the cells we work with. In recent years it has become clear that, in addition to iPLA₂-VIA, other PLA₂s may also be involved in the control of lysophospholipid formation. We are currently trying to determine the molecular nature of these PLA₂s. We are also interested in dissecting other regulatory aspects of lysophospholipid-limited AA incorporation into membrane phospholipids, as well as in delineating the general role of iPLA₂-VIA in homeostatic phospholipid metabolism.

Apart from its homeostatic functions, iPLA₂-VIA may also play other roles in cells. For instance, recent evidence suggests the participation of this enzyme in the destruction of membrane phospholipid subsequent to the cells entering apoptosis (programed cell death). Apoptosis occurs in response to many factors, and one of them is oxidative damage. This is a condition that frequently accompanies a variety of inflammatory states. Phagocytic cells produce substances with high oxidant capacity during inactivation and phagocytosis of invading pathogens. An uncontrolled production of these substances may negatively impact on phagocytic cell function and compromise the resolution of inflammation.

Oxidative damage results in the loss of significant quantities of free fatty acids from cells. We have shown that in U937 phagocytic cells, iPLA₂-VIA mediates phospholipid hydrolysis and fatty acid release in response to hydrogen peroxide exposure. We are currently trying to elucidate the molecular mechanisms leading to augmented iPLA₂-VIA activity during oxidative stress and the ensuing apoptotic response. The ultimate goal of these studies is to provide clues to understand the molecular processes involved in oxidative damage, which in turn may help uncover new molecular targets with possible therapeutic potential.

On the other hand, exposure of phagocytic cells to immunoinflammatory stimuli that act through cell surface receptors results in the tightly-controlled activation of another intracellular PLA₂, the Group IVA cytosolic PLA₂α (cPLA₂α). Under these conditions, the rate of AA liberation clearly exceeds that of reincorporation into phospholipids; hence, net accumulation of free AA occurs that is followed by its conversion into different classes of eicosanoids. In many instances, a third PLA₂ form participates in the process, usually acting to amplify the cPLA₂α-regulated AA mobilization response. This is the inducible secreted PLA₂ (sPLA₂), of which there are several group types. The most prominent with regard to AA release are those of Groups IIA and V. Interestingly, cross-talk appears to exist between cPLA₂α and sPLA₂ during cellular activation. We are currently characterizing different molecular aspects of this cross-talk in phagocytes, and have also begun studies to localize the intracellular sites of action of all these PLA₂s during cellular stimulation by different agonists.



Cyclooxygenase-2 (COX-2) is an inducible enzyme that initiates the biosynthesis of prostaglandins by converting free arachidonic acid into the precursor prostaglandin H₂. COX-2 plays important roles in inflammation and, more recently, has also been demonstrated to play a role in tumor progression by regulating angiogenesis. Our previous studies established that in murine macrophages, COX-2 gene expression is dependent upon the activity of another inducible enzyme, the aforementioned Group V PLA₂. The molecular mechanism implicated in the regulation of COX-2 expression and activity by Group V PLA₂ remains unknown. Defining such a mechanism is another of the goals of our current research efforts.

(Results & Publications sections, up to 2011 – The Eicosanoid Research Division – www.balsinde.org)

REFERENCES

1. Balsinde, J. 2002. Roles of various phospholipases A₂ in providing lysophospholipid acceptors for fatty acid phospholipid incorporation and remodelling. *Biochem. J.* 364: 695–702.
2. Balboa, M. A., and J. Balsinde. 2002. Involvement of calcium-independent phospholipase A₂ in hydrogen peroxide-induced accumulation of free fatty acids in human U937 cells. *J. Biol. Chem.* 277: 40384–40389.
3. Balboa, M. A., Y. Sáez, and J. Balsinde. 2003. Calcium-independent phospholipase A₂ is required for lysozyme secretion in U937 promonocytes. *J. Immunol.* 170: 5276–5280.
4. Balboa, M. A., R. Pérez, and J. Balsinde. 2003. Amplification mechanisms of inflammation: paracrine stimulation of arachidonic acid mobilization by secreted phospholipase A₂ is regulated by cytosolic phospholipase A₂-derived hydroperoxyeicosatetraenoic acid. *J. Immunol.* 171: 989–994.
5. Fuentes, L., R. Pérez, M.L. Nieto, J. Balsinde, and M.A. Balboa. 2003. Bromoenol lactone promotes cell death by a mechanism involving phosphatidate phosphohydrolase-1 rather than calcium-independent phospholipase A₂. *J. Biol. Chem.* 278: 44683–44690.

6. Pérez, R., R. Melero, M.A. Balboa, and J. Balsinde. 2004. Role of group VIA calcium-independent phospholipase A₂ in arachidonic acid release, phospholipid fatty acid incorporation, and apoptosis in U937 cells responding to hydrogen peroxide. *J. Biol. Chem.* 279: 40385-40391.
7. Balsinde, J., and M.A. Balboa. 2005. Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A₂ in activated cells. *Cell. Signal.* 17: 1052-1062.
8. Casas, J., M.A. Gijón, A.G. Vigo, M.S. Crespo, J. Balsinde, and M.A. Balboa. 2006. Phosphatidylinositol 4,5-bisphosphate anchors cytosolic group IVA phospholipase A₂ to perinuclear membranes and decreases its calcium requirement for translocation in live cells. *Mol. Biol. Cell* 17: 155-162.
9. Pérez, R., M. A. Balboa, and J. Balsinde. 2006. Involvement of group VIA calcium-independent phospholipase A₂ in macrophage engulfment of hydrogen peroxide-treated U937 cells. *J. Immunol.* 176: 2555-2561.
10. Pérez, R., X. Matabosch, A. Llebaria, M.A. Balboa, and J. Balsinde. 2006. Blockade of arachidonic acid incorporation into phospholipids induces apoptosis in U937 promonocytic cells. *J. Lipid Res.* 47: 484-491.
11. Casas, J., M.A. Gijón, A.G. Vigo, M.S. Crespo, J. Balsinde, and M.A. Balboa. 2006. Overexpression of cytosolic group IVA phospholipase A₂ protects cells from calcium-dependent death. *J. Biol. Chem.* 281: 6106-6116.
12. Balboa, M. A., and J. Balsinde. 2006. Oxidative stress and arachidonic acid mobilization. *Biochim. Biophys. Acta* 1761: 385-391.
13. Balsinde, J., R. Pérez, and M.A. Balboa. 2006. Calcium-independent phospholipase A₂ and apoptosis, *Biochim. Biophys. Acta* 1761: 1344-1350.
14. Ruipérez, V., J. Casas, M. A. Balboa, and J. Balsinde. 2007. Group V phospholipase A₂-derived lysophosphatidylcholine mediates cyclooxygenase-2 induction in lipopolysaccharide-stimulated macrophages. *J. Immunol.* 179: 631-638.
15. Pindado, J., J. Balsinde, and M. A. Balboa. 2007. TLR3-dependent induction of nitric oxide synthase in RAW 264.7 macrophage-like cells via a cytosolic phospholipase 2/cyclooxygenase-2 pathway. *J. Immunol.* 179: 4821-4828.
16. Balboa, M. A., R. Pérez, and J. Balsinde. 2008. Calcium-independent phospholipase A₂ mediates proliferation of human promonocytic U937 cells. *FEBS J.* 275: 1915-1924.
17. Balgoma, D., O. Montero, M. A. Balboa, and J. Balsinde. 2008. Calcium-independent phospholipase A₂-mediated formation of 1,2-diarachidonoylglycerophosphoinositol in monocytes. *FEBS J.* 275: 6180-6191.
18. Ruipérez, V., A. M. Astudillo, M. A. Balboa, and J. Balsinde. 2009. Coordinate regulation of TLR-mediated arachidonic acid mobilization in macrophages by group IVA and group V phospholipase A₂s. *J. Immunol.* 182: 3877-3883.
19. Casas, J., C. Meana, E. Esquinas, M. Valdearcos, J. Pindado, J. Balsinde, and M. A. Balboa. 2009. Requirement of JNK-mediated phosphorylation for translocation of group IVA phospholipase A₂ to phagosomes in human macrophages. *J. Immunol.* 183: 2767-2774.
20. Pérez-Chacón, G., A. M. Astudillo, D. Balgoma, M. A. Balboa, and J. Balsinde. 2009. Control of free arachidonic acid levels by phospholipases A₂ and lysophospholipid acyltransferases. *Biochim. Biophys. Acta* 1791: 1103-1113.
21. Pérez-Chacón, G., A. M. Astudillo, V. Ruipérez, M. A. Balboa, and J. Balsinde. 2010. Signaling role for lysophosphatidylcholine acyltransferase 3 in receptor-regulated arachidonic acid reacylation reactions in human monocytes. *J. Immunol.* 184: 1071-1078.
22. Casas, J., M. Valdearcos, J. Pindado, J. Balsinde, and M. A. Balboa. 2010. The cationic cluster of group IVA phospholipase A₂ (Lys488/Lys541/Lys543/Lys544) is involved in translocation of the enzyme to phagosomes in human macrophages. *J. Lipid Res.* 51: 388-399.
23. Balgoma, D., A. M. Astudillo, G. Pérez-Chacón, O. Montero, M. A. Balboa, and J. Balsinde. 2010. Markers of monocyte activation revealed by lipidomic profiling of arachidonic acid-containing phospholipids. *J. Immunol.* 184: 3857-3865.
24. Balgoma, D., O. Montero, M. A. Balboa, and J. Balsinde. 2010. Lipidomic approaches to the study of phospholipase A₂-regulated phospholipid fatty acid incorporation and remodeling. *Biochimie* 92: 645-650.

25. Diez, E., J. Balsinde, M. Aracil, and A. Schüller. 1987. Ethanol induces release of arachidonic acid but not synthesis of eicosanoids in mouse peritoneal macrophages. *Biochim. Biophys. Acta* 921: 82–89.
26. Balsinde, J., B. Fernández, and E. Diez. 1990. Regulation of arachidonic acid release in mouse peritoneal macrophages. The role of extracellular calcium and protein kinase C. *J. Immunol.* 144: 4298–4304.
27. Balsinde, J., B. Fernández, J.A. Solís-Herruzo, and E. Diez. 1992. Pathways for arachidonic acid mobilization in zymosan-stimulated mouse peritoneal macrophages. *Biochim. Biophys. Acta* 1136: 75–82.
28. Balsinde, J., B. Fernández, and J.A. Solís-Herruzo. 1994. Increased incorporation of arachidonic acid into phospholipids in zymosan-stimulated mouse peritoneal macrophages. *Eur. J. Biochem.* 221: 1013–1018.
29. Fernández, B. & Balsinde, J. 1991. Receptor-mediated activation of arachidonic acid release in mouse peritoneal macrophages is linked to extracellular calcium influx. *Biochem. Biophys. Res. Commun.* 180: 1036–1040.